Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Equity Ratio: 2016-2025

Historic Equity Ratio for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to 0.50.

  • Organogenesis Holdings' Equity Ratio fell 19.82% to 0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.50, marking a year-over-year decrease of 19.82%. This contributed to the annual value of 0.53 for FY2024, which is 12.83% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Equity Ratio is 0.50, which was down 1.06% from 0.51 recorded in Q2 2025.
  • Organogenesis Holdings' 5-year Equity Ratio high stood at 0.62 for Q3 2024, and its period low was 0.49 during Q1 2021.
  • For the 3-year period, Organogenesis Holdings' Equity Ratio averaged around 0.57, with its median value being 0.59 (2024).
  • In the last 5 years, Organogenesis Holdings' Equity Ratio skyrocketed by 204.72% in 2021 and then decreased by 19.82% in 2025.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Equity Ratio stood at 0.54 in 2021, then rose by 8.59% to 0.59 in 2022, then rose by 2.46% to 0.61 in 2023, then declined by 12.83% to 0.53 in 2024, then declined by 19.82% to 0.50 in 2025.
  • Its Equity Ratio stands at 0.50 for Q3 2025, versus 0.51 for Q2 2025 and 0.52 for Q1 2025.